Biblio

Found 22 results
[ Author(Asc)] Keyword Title Type Year
Filters: First Letter Of Last Name is B  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
B
L. Butler, Bacon, M., Carey, M. S., Zee, B., Tu, D., and Bezjak, A., Determining the relationship between toxicity and quality of life in an ovarian cancer chemotherapy clinical trial., J Clin Oncol, vol. 22, no. 12, pp. 2461-8, 2004.
A. Buda, Fossati, R., Colombo, N., Fei, F., Floriani, I., D. Alletti, G., Katsaros, D., Landoni, F., Lissoni, A., Malzoni, C., Schröder, W., Scollo, P., Torri, V., Zola, P., and Mangioni, C., Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Por, J Clin Oncol, vol. 23, pp. 4137-45, 2005.
M. Brundage, Gropp, M., Mefti, F., Mann, K., Lund, B., Gebski, V., Wolfram, G., Reed, N. Simon, Pignata, S., Ferrero, A., Brown, C., Eisenhauer, E., and Pujade-Lauraine, E., Health-related quality of life in recurrent platinum-sensitive ovarian cancer--results from the CALYPSO trial., Ann Oncol, vol. 23, no. 8, p. 2027, 2012.
J. Brown, Friedlander, M. Leonard, Backes, F. J., Harter, P., O'Connor, D. M., Rouge, Tde la Mott, Lorusso, D., Maenpaa, J. U., Kim, J. - W., Tenney, M. E., and Seckl, M. J., Gynecologic Cancer Intergroup (GCIG) consensus review for ovarian germ cell tumors., Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S48-54, 2014.
L. Brotto, Brundage, M., Hoskins, P., Vergote, I. B., Cervantes, A., Casado, H. A., Poveda, A. M., Eisenhauer, E., and Tu, D., Randomized study of sequential cisplatin-topotecan/carboplatin-paclitaxel versus carboplatin-paclitaxel: effects on quality of life., Support Care Cancer, vol. 24, no. 3, p. 1249, 2016.
M. F. Brady, Thigpen, J. T., Vermorken, J. B., and Parmar, M. K. B., Randomised trials in ovarian cancer: trial design considerations., Ann Oncol, vol. 10 Suppl 1, pp. 75-82, 1999.
H. Bourgeois, Joly, F., Pujade-Lauraine, E., Curé, H., Guastalla, J. P., Ferru, A., Chabrun, V., Chieze, S., and Tourani, J. M., Phase I study of pegylated liposomal doxorubicin in combination with ifosfamide in pretreated ovarian cancer patients, Am J Clin Oncol, vol. 29, pp. 399-404, 2006.
M. A. Bookman, Greer, B. E., and Ozols, R. F., Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel versus cisplatin and paclitaxel (GOG158) and an update on GOG0182-ICON5., Int J Gynecol Cancer, vol. 13 Suppl 2, pp. 149-55, 2003.
M. A. Bookman, Greer, B. E., and Ozols, R. F., Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5, Int J Gynecol Cancer, vol. 13, pp. 735-40, 2003.
M. A. Bookman, Brady, M. F., McGuire, W. P., Harper, P. G., Alberts, D. S., Friedlander, M. Leonard, Colombo, N., Fowler, J. M., Argenta, P. A., De Geest, K., Mutch, D. G., Burger, R. A., Swart, A. Marie, Trimble, E. L., Accario-Winslow, C., and Roth, L. M., Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup., J Clin Oncol, vol. 27, no. 9, pp. 1419-25, 2009.
M. A. Bookman, Okamoto, A., Stuart, G. C. E., Yanaihara, N., Aoki, D., Bacon, M., Fujiwara, K., González-Martín, A., Harter, P., Kim, J. W., Ledermann, J. A., Pujade-Lauraine, E., Quinn, M., and Ochiai, K., Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference., Ann Oncol, vol. 28, no. suppl_8, pp. viii30-viii35, 2017.
A. Bezjak, Tu, D., Bacon, M., Osoba, D., Zee, B., Stuart, G. C. E., Roy, J. - A., Piccart, M. J., and Eisenhauer, E., Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study., J Clin Oncol, vol. 22, no. 22, pp. 4595-603, 2004.
D. Berton-Rigaud, Devouassoux-Shisheboran, M., Ledermann, J. A., Leitao, M. M., Powell, M. A., Poveda, A. M., Beale, P., Glasspool, R. M., Creutzberg, C. L., Harter, P., Kim, J. - W., Reed, N. Simon, and Ray-Coquard, I., Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma., Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S55-60, 2014.
K. Bertelsen, Grenman, S., and Rustin, G. J. S., How long should first-line chemotherapy continue?, Ann Oncol, vol. 10 Suppl 1, pp. 17-20, 1999.
J. S. Berek, Bertelsen, K., du Bois, A., Brady, M. F., Carmichael, J., Eisenhauer, E., Gore, M. E., Grenman, S., Hamilton, T. C., Hansen, S. W., Harper, P. G., Horvath, G., Kaye, S. B., Lück, H. J., Lund, B., McGuire, W. P., Neijt, J. P., Ozols, R. F., Parmar, M. K. B., Piccart, M. J., van Rijswijk, R., Rosenberg, P., Rustin, G. J. S., Sessa, C., Thigpen, J. T., Tropé, C. G., Tuxen, M. K., Vergote, I. B., Vermorken, J. B., and Willemse, P. H., [Epithelial ovarian cancer (advanced stage): consensus conference (1998)]., Gynecol Obstet Fertil, vol. 28, no. 7-8, pp. 576-83, 2000.
J. S. Berek, Bertelsen, K., du Bois, A., Brady, M. F., Carmichael, J., Eisenhauer, E., Gore, M. E., Grenman, S., Hamilton, T. C., Hansen, S. W., Harper, P. G., Horvath, G., Kaye, S. B., Lück, H. J., Lund, B., McGuire, W. P., Neijt, J. P., Ozols, R. F., Parmar, M. K. B., Piccart, M. J., van Rijswijk, R., Rosenberg, P., Rustin, G. J. S., Sessa, C., and Willemse, P. H., Advanced epithelial ovarian cancer: 1998 consensus statements., Ann Oncol, vol. 10 Suppl 1, pp. 87-92, 1999.
J. G. Bell, Brady, M. F., Young, R. C., Lage, J., Walker, J. L., Look, K. Y., Rose, G. S., Spirtos, N. M., and Group, G. Oncology, Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study, Gynecol Oncol, vol. 102, pp. 432-9, 2006.
S. V. Barrett, Paul, J., Hay, A., Vasey, P. A., Kaye, S. B., Glasspool, R. M., and Group, S. Gynaecolog, Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial, Ann Oncol, vol. 19, pp. 898-902, 2008.
R. R. Barakat, Bundy, B. N., Spirtos, N. M., Bell, J. G., Mannel, R., and Study, G. Oncology G., Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study, J Clin Oncol, vol. 24, pp. 587-92, 2006.
S. Banerjee, Rustin, G. J. S., Paul, J., Williams, C., Pledge, S., Gabra, H., Skailes, G., Lamont, A., Hindley, A., Goss, G., Gilby, E., Hogg, M., Harper, P., Kipps, E., Lewsley, L. A., Hall, M., Vasey, P. A., and Kaye, S. B., A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG., Ann Oncol, vol. 24, no. 3, p. 687, 2013.
M. Bagnoli, Shi, T. Yan, Gourley, C., Speiser, P., Reuss, A., Nijman, H. W., Creutzberg, C. L., Scholl, S., Negrouk, A., Brady, M. F., Hasegawa, K., Oda, K., McNeish, I. A., Kohn, E. C., Oza, A. M., MacKay, H., Millan, D., Bennett, K., Scott, C., and Mezzanzanica, D., Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions., Cells, vol. 8, no. 3, 2019.
M. Bacon, Kitchener, H. C., Stuart, G. C. E., and Vermorken, J. B., The global impact of the Gynecologic Cancer InterGroup in enhancing clinical trials in ovarian cancer., Int J Gynecol Cancer, vol. 21, no. 4, pp. 746-9, 2011.